|
- Sources: Elad Gil is raising a fund of ~$1. 5B that could grow to $2B . . .
Sources: Elad Gil is raising a fund of ~$1 5B that could grow to $2B based on investor interest, making it one of the largest fundraising hauls for a solo GP — Venture capital firms are under pressure to make rapid-fire decisions about big checks in the frenzied world of artificial intelligence investing …
- From Elad Gil to Matt Miller: Why venture GPs keep going solo
Just this month, two heavyweights of legacy firms— Sequoia ‘s Matt Miller and Two Sigma ‘s Villi Iltchev—announced they were going solo They’re far from alone Last year, Elad Gil, the industry’s most prominent solo GP, became the first to raise a billion-dollar fund
- Promising New Data Support GLP-1s for Dementia Prevention
In the phase 2b ELAD clinical trial, adults with early-stage Alzheimer's disease (AD) taking the GLP-1 receptor agonist liraglutide exhibited slower decline in memory and thinking and
- Sources: Elad Gil is raising a fund of ~$1. 5B that - One News Page
Sources: Elad Gil is raising a fund of ~$1 5B that could grow to $2B based on investor interest, making it one of the largest fundraising hauls for a solo GP Published 25 Jul 2025
- GLP-1 Analog Slows Cognitive Decline; Potential Alzheimer Disease . . .
The study author conducted a multicenter, randomized, double-blind, placebo-controlled, phase 2b trial (Effects of the Novel GLP-1 Analogue Liraglutide in Alzheimer’s Disease; ELAD) at 24 clinics throughout the United Kingdom to determine the neuroprotective effects of liraglutide
- Sources: repair demand in China for Nvidias banned AI chips, including . . .
Sources: Elad Gil is raising a fund of ~$1 5B that could grow to $2B based on investor interest, making it one of the largest fundraising hauls for a solo GP X: @nmasc_
- Older GLP-1 drug shows glimmer of benefit in Alzheimers
It's possible that Alzheimer's disease could be added to the lengthening list of health conditions that can be improved by treatment with GLP-1 receptor agonists
- Evaluating Liraglutide in Alzheimers Disease (ELAD)
This is a 12-month, multicentre randomised double-blind placebo-controlled Phase IIb study in patients with mild Alzheimer's dementia (AD) Patients will be randomised on a 1:1 ratio to receive liraglutide or matching placebo
|
|
|